Trial Profile
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov (NCT01364038).